Abstract

There is no echocardiographic predictor of the effectiveness of tolvaptan in patients with heart failure (HF). The aim of this study was to investigate the echocardiographic predictor of responders to tolvaptan in patients with HF. This observational study consisted of 62 consecutive in-hospital patients with HF who received tolvaptan with volume overload despite standard therapies. The echocardiography data were obtained within 1week before the administration of tolvaptan. Tolvaptan responders were defined as those having a body weight decrease from baseline >1kg on the morning of day 8. The mean age of the 62 patients was 75.1±13.9years, and 45 patients (72.6%) were considered to be responders. Tricuspid annular plane systolic excursion (TAPSE) was significantly higher (17.1±3.8 vs. 13.0±3.9mm; p=0.0004) and the tricuspid valve regurgitation pressure gradient (33.3±14.6 vs. 44.9±12.2mmHg; p=0.007) and estimated right atrium pressure (7.8±4.2 vs. 10.3±4.5mmHg; p=0.043) were significantly lower in the Responder group than in the Non-responder group. In a multivariate logistic regression analysis, TAPSE was found to be an independent predictor of response (odds ratio 1.28; 95% confidence interval 1.03-1.60). According to the receiver operating characteristics analysis, the area under the curve of TAPSE was the largest among the parameters measured by echocardiography. The cut-off value for TAPSE to predict responders was determined to be 17.0mm (sensitivity=56.8%, specificity=94.1%). TAPSE is a simple predictor of the effectiveness of tolvaptan in patients with HF.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call